BSc, Umeå University, is member of several company boards e.g. the board of Uminova Invest AB, Uminova Innovation AB and chairman of Umeå Biotech Incubator AB (UBI). Kenth Bergström has some 20 years experience from the industry, e.g. as Vice President of GE Healthcare and Amersham Biosciences, respectively, and experience from the market organisation of companies e.g. Pharmacia and ABB.

MD, PhD, co-founder and CEO of Umecrine AB, is currently professor at the Department of Clinical Science, Obstetrics and Gynecology, Umeå University. He is also head of the Umeå Neurosteroid Research Center. Professor Bäckström's main focus of research since 1972 is the effect of sex and stress hormones on the brain and conditions induced by these hormones, he has more than 400 scientific publications within this area and he is a frequently invited key-note speaker at scientific meetings around the world.

Otto Skolling (Adj.) has a M.Sc. in Chemistry, VP Business Development at Karolinska Development AB, has 20 years of broad-based pharmaceutical and med tech. industry experience, including product development, business development and project management gained through management positions at Novozymes, Siemens Life Support Systems and Pharmacia & Upjohn.

Tomas Odergren, M.D., Ph.D., Director of the Board is a certified neurologist with 10 years of clinical practice and a Ph.D. at the Karolinska Institute. Dr Odergren has 17 years of pharmaceutical industry experience from senior positions at AstraZeneca R&D, including Vice President for Project Management for the CNS and pain Innovative Medicines and Global Vice President for the Onglyza franchise and currently as VP Clinical at Karolinska Development.

Pharmacist, and Investment Manager at Karolinska Development AB, has more than 30 years of experience from different positions within development in the pharmaceutical industry, e.g. AstraZeneca, Apoteksbolaget, ACO and Kabi. Other board assignments include Axelar, Biosergen, Calabar and Oncopeptides.